Crescent Biopharma Appoints Jan Pinkas, Ph.D., as Chief Scientific Officer
Seasoned Leader Brings Deep Experience in Oncology Drug Development as Company Advances Portfolio of Next Generation Therapeutics for Solid Tumors...
Clinical Trial
Jade Biosciences to Participate in Two Upcoming Investor Conferences
SAN FRANCISCO and VANCOUVER, British Columbia, July 08, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), (Nasdaq: JBIO), a biotechnology...
Eupraxia Doses First Patient in Phase 2b Placebo-Controlled Portion of EP-104GI RESOLVE Trial in Eosinophilic Esophagitis
Dosing of the first patient in Phase 2b marks an important transition of the RESOLVE trial from a Phase 2a...
Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD)
– Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24...
Larimar Therapeutics Publishes Nonclinical Data Supporting the Therapeutic Potential of Nomlabofusp in Patients with Friedreich’s Ataxia
Nonclinical findings provide evidence of the mechanism of action of nomlabofusp and support the potential use of skin FXN concentrations...
Agios Appoints Dr. Jay Backstrom to Board of Directors
CAMBRIDGE, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate...
ProKidney Reports Statistically and Clinically Significant Topline Results for the Phase 2 REGEN-007 Trial Evaluating Rilparencel in Patients with Chronic Kidney Disease and Diabetes
Full results from REGEN-007 are being held and will be submitted to the American Society of Nephrology 2025 Kidney Week...
Comphya Closes Oversubscribed CHF 7.5 Million Series A Round to Advance U.S. and Australian Clinical Programs Following Strong Pilot Data
- IDE approval obtained; U.S. pilot study clinical site launched at Johns Hopkins- Series B round in planning to support...
Novartis receives approval for first malaria medicine for newborn babies and young infants
Coartem® (artemether-lumefantrine) Baby becomes first malaria treatment approved for newborn babies and young infants Rapid approvals in eight African countries...
Medicus Pharma Ltd. Announces Submission of Type C Meeting Request to the Food and Drug Administration (FDA)
The Company's aim is to seek FDA consent to fast track the Clinical Development Program to treat Basal Cell Carcinoma...
Veeda Lifesciences announces partnership with Mango Sciences to bring AI innovation in clinical trials services
AHMEDABAD, India, July 8, 2025 /PRNewswire/ -- Veeda Lifesciences, a global contract research organization (CRO), has announced an investment in...
KORU Medical Systems Appoints Adam Kalbermatten as Chief Commercial Officer
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on...
NervGen Provides Quarterly “At-The-Market” Equity Program and Grant of Options Update
Vancouver, British Columbia--(Newsfile Corp. - July 7, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage...
Sitero Signs Agreement to Acquire Axiom Real-Time Metrics, Expanding Global Footprint and Strengthening Technology-Enabled Clinical Services
MIAMI, Fla., July 7, 2025 /PRNewswire/ -- Sitero, a leading provider of clinical and regulatory services, today announced that it...
Boston Scientific receives FDA approval for expanded labeling of FARAPULSE™ Pulsed Field Ablation System
The FARAPULSE PFA System now approved for pulmonary vein and posterior wall ablation in patients with persistent atrial fibrillation MARLBOROUGH,...
BEAR MOON Study of Miach Orthopaedics’ BEAR® Implant Completes Enrollment
NIH-Sponsored Study Compares BEAR Implant to ACL Reconstruction for Complete ACL TearsWESTBOROUGH, Mass.--(BUSINESS WIRE)--#ACLrepair--Miach Orthopaedics, Inc., a company transforming the...
Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and Glioblastoma
In an ongoing Phase 1 trial published in Nature Medicine, MB-101 was well-tolerated and 50% of patients achieved stable disease...
Conduit Pharmaceuticals Files New Patents Following AI-Driven Combination Discoveries
Includes Conduit’s first composition of matter patent filing for AZD5658 and multiple new combination filings for AZD1656 and AZD5658Patents derived...
Silo Pharma Advances PTSD Drug SPC-15 Toward Planned 2025 IND Submission with Pre-Clinical Study Data Expected in Q3 2025
Planned submission of IND application in 2025; Phase 1 clinical trial to follow if IND application approved No new PTSD...
Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer
TARPON SPRINGS, Fla., July 7, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase...